S
uspected sepsis is a common cause of morbidity and mortality in neonates. In a population-based surveillance study 1 from 2005 to 2008, researchers estimated that 3300 cases of early-onset sepsis (EOS) occur in the United States each year, with 390 of these cases resulting in death. The risk is highest in preterm neonates, which account for 1570 of the 3300 cases and 360 deaths. 1 Despite its prevalence, though, identifying patients with sepsis, determining causative organisms, and establishing a length of treatment remain a challenge for health care practitioners.
Sepsis in neonates can be classified as either early onset or late onset. No single definition for EOS exists, but most often it is described as infection of the bloodstream or meninges that occurs within the first 6 days of life. 2 The most commonly implicated organisms are group B streptococci (GBS) and Escherichia coli, which are most often acquired via vertical transmission from the mother during the intrapartum period. 1 In general, GBS is most prevalent in term neonates, whereas E coli is more attributable to EOS in preterm and low-birth-weight infants. 1, 3 Late-onset sepsis occurs after the first week of life and is associated with nosocomial organisms acquired via horizontal transmission. Thus, awareness of the timing of the onset of sepsis can be helpful in determining initial empiric antimicrobial therapy for the neonate.
Identifying Sepsis
Symptoms of sepsis are nonspecific and can be seen in noninfectious conditions, making diagnosis difficult. White blood cell count and platelet count have poor predictive value. Absolute neutrophil count, the presence of bands, and the immature to total neutrophil ratio are often more useful in excluding a diagnosis of sepsis, rather than confirming it. 4 Neutropenia may have better specificity in EOS because few other conditions will suppress the neutrophil count in a neonate; however, the definition for neutropenia varies with gestational age, type of delivery, site of sampling, and altitude.
A single blood specimen for culture consisting of at least 1 mL of volume is necessary for all neonates with suspected sepsis. Volumes less than 1 mL are unlikely to be sufficient for identification of low-level bacteremia, and splitting the 1-mL sample into aerobic and anaerobic bottles is also not recommended. Lumbar punctures remain controversial in the neonatal population and should be reserved for neonates with blood cultures that show growth of microorganisms, laboratory values strongly suggestive of bacterial sepsis, and those whose condition worsens while they are receiving antimicrobial therapy. 4 Procalcitonin is a biomarker of inflammatory response, and although this test is relatively new, its clinical utility has been increasing. Study results indicate that procalcitonin may be most specific for bacterial infections and that its increasing and decreasing levels may correspond to the onset and resolution of the infection, respectively. 5, 6 Additionally, a singlecenter study 7 showed that procalcitonin-guided treatment reduced exposure to antibiotics by 22.4 hours. The study was underpowered to detect a difference in morbidity or mortality between the 2 groups, however. 7 C-reactive protein is an acute phase reactant, which is released as a response to sources of inflammation, such as infection or tissue injury. Serial measurements of levels of C-reactive protein are helpful in ruling out sepsis in neonates. The National Institute for Health and Care Excellence (NICE) recommends that the level of C-reactive protein be measured in neonates with risk factors or any other concerns for early-onset infection. 8 In healthy neonates, the normal value for C-reactive protein is less than 1 mg/dL; however, values greater than 1 mg/dL have varying sensitivity and specificity when used for the diagnosis of neonatal sepsis.
Maternal Prophylaxis and Treatment
Group B streptococcal (GBS) disease is the leading cause of neonatal morbidity and mortality, with as many as 1200 cases of EOS being caused by GBS annually. 9 The primary risk factor for GBS disease is maternal intrapartum colonization, which can be transient, intermittent, or persistent. 9 Additional risk factors include being less than 37 weeks' gestation, prolonged membrane rupture, intra-amniotic infection, young maternal age, and black race. Implementation of active prevention against GBS began in the early 1990s and led to significant declines in the incidence of GBS disease. Further declines were seen after the recommendation for universal screening was introduced in 2002. 9 Despite these efforts, though, GBS remains the most common causative organism implicated in EOS.
GBS infections most commonly occur via vertical transmission from the mother when the bacteria ascend from the vagina to the amniotic fluid following rupture of membranes; however, GBS can also penetrate intact membranes. Infants can also aspirate GBS or be exposed to it during passage through the birth canal. Early-onset GBS infections frequently manifest as respiratory distress, apnea, or other signs of sepsis in the first 24 to 48 hours of life. 9 Pneumonia and sepsis are more commonly seen with GBS infection than meningitis. Mortality due to GBS infection is higher in infants less than 33 weeks' gestation than in term infants, with a fatality rate of up to 20% in preterm infants. 9 All mothers who are known to be colonized with GBS should receive intrapartum antibiotic prophylaxis. Ideally, antibiotics should be administered at least 4 hours before delivery in order to have time to achieve adequate levels in fetal circulation and amniotic fluid. 9 Both intravenous penicillin and ampicillin have been extensively studied and have similar efficacy in preventing GBS disease. Common regimens for these agents are listed in Table 1 . 10 Alternative agents that are occasionally used include cefazolin (Ancef), clindamycin (Cleocin), and vancomycin (Vancocin); however, controlled studies evaluating the effectiveness of these antimicrobial agents for GBS prophylaxis are lacking. 9, 11 Preterm premature rupture of membranes (PPROM) is membrane rupture at less than 37 weeks' gestation and before the onset of contractions. 12 Antibiotics should be administered to anyone presenting with PPROM at less than 34 0 /7 weeks' gestation. These antibiotics, often referred to as latency antibiotics, can prolong pregnancy, minimize maternal and fetal infection, and decrease morbidity. The preferred regimen differs from institution to institution, but most commonly consists of ampicillin with or without erythromycin or azithromycin (see Figure) . 12, 13 Alternative treatment options for patients with -lactam allergies are not well established. In addition to latency antibiotics, these patients should also receive expectant management, corticosteroids, and GBS prophylaxis if indicated. If PPROM occurs at 34 weeks' gestation or more, the patient should proceed to delivery and receive GBS prophylaxis if indicated.
Chorioamnionitis is characterized as an acute inflammation of the membranes and chorion of the placenta, often manifesting as a maternal fever, and is a major risk factor for neonatal sepsis, with up to 40% of cases of EOS being associated with chorioamnionitis. In addition to EOS, chorioamnionitis can result in neonatal septic shock, intraventricular hemorrhage, cerebral white matter damage, and death.
14 Antibiotics should be administered to the mother as soon as chorioamnionitis is suspected. Recommendations regarding antibiotic regimens are largely based on consensus, with intravenous ampicillin plus or minus gentamicin being commonly used. Additionally, clindamycin or metronidazole can be added for anaerobic coverage, specifically if a cesarean is performed.
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Treatment of Early-Onset Neonatal Sepsis
The treatment of choice for early-onset neonatal sepsis is based on the common organisms responsible for most infections in this patient population. The combination of ampicillin and gentamicin continue to be the preferred antibiotics for the empiric treatment of EOS.
2 Cefotaxime can be used as an alternative to gentamicin in neonates with renal dysfunction or if there is concern for potential renal dysfunction due to the use of other nephrotoxic agents, such as indomethacin or furosemide.
Ampicillin is a -lactam antibiotic that provides coverage against group B Streptococcus, Listeria, most strains of Staphylococcus, susceptible strains of E coli, and some strains of Haemophilus influenzae. Dosing of ampicillin is dependent on the neonate's postmenstrual age and day of life. Several dosing regimens exist for ampicillin, and which regimen is used is dependent on indication and local resistance patterns (Table 2) . 15, 16 Ampicillin is primarily excreted renally, and monitoring of levels is not necessary. 15 Gentamicin is an aminoglycoside antibiotic which is most effective against gram-negative organisms, such as E coli, Pseudomonas, and Proteus; however, it can also be effective for group B Streptococcus and Enterococcus if used in combination with ampicillin. Dosing of gentamicin is dependent on the neonate's postmenstrual age and day of life (Table 2) . If treating for more than 48 hours, peak and trough levels should be measured. Samples to determine peak concentrations are collected 30 minutes after the end of the infusion, and therapeutic concentrations are 5 to 12 μg/mL. Samples to determine trough concentrations are collected just before the scheduled dose of gentamicin. There is a lack of consensus on goal trough level, however, with some references suggesting that troughs should be less than 1 μg/mL and others suggesting a trough less than 2 μg/mL, especially for serious infections. 13, 14 Gentamicin has been associated with neurotoxic, nephrotoxic, and ototoxic effects. common in neonates who are dehydrated, have decreased urine output, or who are receiving other nephrotoxic agents. 15, 16 Cefotaxime is a third-generation cephalosporin that provides coverage against gramnegative bacteria including E coli, Haemophilus influenza, and Klebsiella. Dosing regimens are listed in Table 2 . Adverse effects with cefotaxime are rare, but include rash, phlebitis, diarrhea, leukopenia, granulocytopenia, and eosinophilia. Monitoring of serum levels is not recommended for cefotaxime, but a complete blood cell count should be done periodically, especially for prolonged treatment courses. 15 
Hemodynamic Support
In neonates, sepsis may progress to septic shock, resulting in cardiovascular collapse and the need for fluid resuscitation, vasopressors, or inotropic agents. Unfortunately, there is no "one size fits all" for blood pressure and hemodynamic monitoring in neonates with septic shock. Some data support the use of a mean arterial pressure (MAP) of 30 mm Hg or greater to sustain blood flow to the brain and other vital organs. 17 A threshold based on gestational age (weeks of gestation completed at the time of birth) is used at many institutions, with the goal being to maintain MAP above gestational age, especially during the first 72 hours of life (ie, an infant born at 28 weeks' gestation should have a MAP > 28 mm Hg, whereas an infant born at 34 weeks' gestation should have a MAP > 34 mm Hg). 18 More evidence is needed to support the use of a specific metric that is accurate for assessing organ perfusion and the therapeutic goal associated with that metric.
Generally, fluid resuscitation is the recommended initial treatment for sepsis and should take place within the first hour of suspected septic shock. Although evidence to support its use is lacking, a single crystalloid fluid bolus of 10 to 20 mL/kg infused for 30 to 60 minutes, but in as short a time as 5 to 10 minutes, is an accepted practice for the initial management of hypotension in neonatal septic shock. [17] [18] [19] Term infants may receive more aggressive volume expansion (20-40 mL/kg), though it should be noted that there is a risk for intracranial hemorrhage with rapid volume expansion in newborns, especially within the first 3 days of life. 18 Dopamine is generally the first-line vasopressor for fluid-refractory septic shock because of its positive effect on blood pressure with a low likelihood of adverse effects compared with other vasopressors. 18, 20 Epinephrine is another effective option, however, it is not as well tolerated because of a higher incidence of adverse effects, but it may reverse dopamine refractory shock. 15, 19 Dobutamine is not as commonly used as dopamine, but it may play a role in septic shock due to poor perfusion from reduced myocardial contractility. Along with epinephrine, norepinephrine and vasopressin are being studied for their role in dopamine refractory hypotension. 19, 20 Milrinone, a phosphodiesterase inhibitor and positive inotrope, has not been studied in neonatal septic shock but has been used in children. 18 Dose ranges and adverse effects for vasopressors and inotropic agents in neonates are shown in Table 3 . Hydrocortisone is reserved for pressorresistant septic shock. It is a last-line option for the management of refractory hypotension and also may help facilitate weaning off of vasoactive medications. 20 Hydrocortisone use may correct underlying adrenal insufficiency, contributing to septic shock and resistant hypotension. Basal cortisol levels and cosyntropin-stimulated cortisol levels may be of value in measuring the degree of adrenal suppression in the neonate. Several different dosing techniques for intravenous hydrocortisone in the setting of pressor-resistant hypotension have been suggested (Table 3) .
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Conclusion
Early-onset sepsis remains a common cause of morbidity and mortality in both term and preterm neonates. Unfortunately, nonspecific symptoms and the lack of definitive laboratory tests continue to make identifying sepsis a challenge for health care providers. An understanding of maternal and neonatal risk factors for EOS can aid not only in the diagnosis of sepsis, but also in the selection of empiric antibiotic therapy. Additional studies to identify better diagnostic tests and hemodynamic goals are needed in this patient population.
a Phentolamine 1 mg/mL may be injected to treat vasopressor-infiltrated areas. Usual dose is 1 to 5 mL. 
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